These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Nannini C; West CP; Erwin PJ; Matteson EL Arthritis Res Ther; 2008; 10(5):R124. PubMed ID: 18937831 [TBL] [Abstract][Full Text] [Related]
9. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Strange C; Bolster MB; Roth MD; Silver RM; Theodore A; Goldin J; Clements P; Chung J; Elashoff RM; Suh R; Smith EA; Furst DE; Tashkin DP; Am J Respir Crit Care Med; 2008 Jan; 177(1):91-8. PubMed ID: 17901414 [TBL] [Abstract][Full Text] [Related]
10. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy. Jain S; Shahane A; Derk CT Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881 [TBL] [Abstract][Full Text] [Related]
11. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Henness S; Wigley FM Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543 [TBL] [Abstract][Full Text] [Related]
12. [Management of patients with systemic sclerosis]. Wiesik-Szewczyk E; Olesińska M Pol Merkur Lekarski; 2010 May; 28(167):421-3. PubMed ID: 20568411 [TBL] [Abstract][Full Text] [Related]
13. Drug treatment of scleroderma. Leighton C Drugs; 2001; 61(3):419-27. PubMed ID: 11293650 [TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide in scleroderma lung disease. Andreu JL; Silva L N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700 [No Abstract] [Full Text] [Related]
15. Systemic Sclerosis and Pulmonary Disease. Ngo K Adv Exp Med Biol; 2021; 1303():173-182. PubMed ID: 33788193 [TBL] [Abstract][Full Text] [Related]
16. Scleroderma lung: pathogenesis, evaluation, and current therapy. Co HT; Block JA; Sequeira W Am J Ther; 2000 Sep; 7(5):321-4. PubMed ID: 11317180 [TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis. Vallance DK; Lynch JP; McCune WJ Curr Opin Rheumatol; 1995 May; 7(3):174-82. PubMed ID: 7612408 [TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide in scleroderma lung disease. Kuschner WG N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726 [No Abstract] [Full Text] [Related]
19. [Cardiac and pulmonary involvement in scleroderma]. Launay D; Hachulla E Rev Prat; 2002 Nov; 52(17):1901-7. PubMed ID: 12532867 [TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Sabnani I; Zucker MJ; Rosenstein ED; Baran DA; Arroyo LH; Tsang P; Zubair M; Rivera V Rheumatology (Oxford); 2009 Jan; 48(1):49-52. PubMed ID: 18815156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]